Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Syndax Pharmaceuticals Inc

NASDAQ: SNDX · Life Sciences · 3 alerts · CIK 1395937

Share price
$9.13Close, Nov 16
Market cap
$815M
Shares outstanding
89.3MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Syndax Pharmaceuticals Inc filings on SEC EDGAR ↗

4:05 PM ET 10-Q
Financial Results

Syndax Pharmaceuticals Q3 2026 Results: Net Loss of $49.4M, Loss Narrows

Syndax Pharmaceuticals reported a significant increase in total revenues to $221.0 million for the nine months ended September 30, 2026, compared to $103.6 million in the prior year, driven by product sales of REVUFORJ and NIKTIMVO. Despite higher revenues, the company recorded a net loss of $141.5 million for the period, though this was an improvement from the $217.4 million loss in 2025. The balance sheet was strengthened by the issuance of a $250 million convertible note.

Key figure
Net loss $49.4M
4:03 PM ET 8-K
Financial Results

Syndax Pharmaceuticals Financial Results

Syndax Pharmaceuticals reported Q3 2026 total revenue of $83.3 million, an 82% year-over-year increase driven by strong sales of Revuforj and Niktimvo. The company also announced a leadership transition with Aaron A. Ondrey appointed as CFO effective November 9, 2026, succeeding the retiring Keith A. Goldan.

“We delivered another quarter of strong commercial results, generating $83 million in total revenue to Syndax. Revuforj net revenue grew to $61 million, driven by a 20% increase in new patients and an increasing number of patients on therapy in the post-transplant setting.”

Michael A. Metzger, Chief Executive Officer

“We look forward to sharing new Revuforj combination data in the fourth quarter that reinforce our confidence that our ongoing pivotal frontline trials could transform the treatment paradigm for newly diagnosed AML. We remain well positioned to be the first to deliver a menin inhibitor in the frontline, unlocking a multi-billion-dollar opportunity.”

Michael A. Metzger, Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.